UCB's investigational small molecule minzasolmin, developed in partnership with Novartis, has failed to meet primary and secondary endpoints in a phase 2a trial for early-stage Parkinson's disease, leading to the termination of its extension phase. The study, which involved 496 patients, showed comparable treatment-emergent adverse events across groups, with no new safety risks identified. UCB continues to explore alpha-synuclein pathology with other candidates, including UCB7583 and glovadalen, the latter of which is in a phase 2 trial with results expected in March 2025.
